Recently, the Phase I Clinical Study to evaluate the Safety and Tolerability of GCK-01 Cell Injection Combined with Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma, sponsored by Beijing Gecell Therapeutics, LLC., was officially launched successively at Ruijin Hospital (Shanghai) (Site 01) and Union Hospital (Wuhan) (Site 02). This milestone event marks a critical step forward in the clinical exploration of this innovative cell therapy in the field of lymphoma, bringing new hope for therapeutic breakthroughs in the treatment of patients with relapsed or refractory follicular lymphoma (R/R FL). 

Addressing Unmet Needs: Innovative Therapy Tackles Relapse and Refractory Dilemma

 As a common indolent non-Hodgkin lymphoma, follicular lymphoma (FL) typically shows a good response to initial treatment. However, the frequent recurrence of the disease and its progression to a refractory state still plague many patients, creating an urgent clinical need for more effective treatment regimens. The Phase I clinical study launched this time centers on the combination therapy of GCK-01 Cell Injection and Rituximab**, aiming to systematically evaluate the safety and tolerability of this combination therapy in patients with R/R FL. It will lay a solid foundation for subsequent dose exploration and efficacy verification, and is expected to fill the treatment gap in this field. 

Sponsor Leadership: Gecell’s Commitment to Cell Therapy Innovation

As the sponsor of this study, Gecell Therapeutics, LLC. has long focused on innovative R&D in cell therapy. Leveraging its technological expertise and R&D capabilities, the company is strategically advancing breakthrough therapies for hematologic malignancies such as lymphoma. The launch of this GCK-01 combination clinical study is a concrete demonstration of Gecell’s mission to “address unmet clinical needs through innovation,” showcasing the company’s forward-looking vision and responsibility in the cell therapy landscape.

Top-Tier Clinical Partners: Dual-Center Collaboration to Ensure Research Excellence

       -Ruijin Hospital (Shanghai) (Site 01): As a top-tier Class III Grade A general hospital in China, its hematology department has deep expertise in lymphoma diagnosis, treatment, and clinical research. Its highly experienced trial management team provides strong support for rigorous study conduct.

  -Union Hospital (Wuhan) (Site 02): Also a well-known Class III Grade A hospital in China, Union Hospital has exceptional strengths in internal medicine and hematologic disease management. Its excellence in clinical trial design and patient management will further ensure efficient trial execution.
        The participation of these two elite centers reflects strong recognition of the GCK-01 combination therapy by top clinical institutions in China, while also reinforcing the trial’s robustness in terms of study quality, patient recruitment, and overall execution. 

Industry Impact: Accelerating the Innovation of Cell Therapy in Lymphoma

  Phase I clinical study is a critical starting point for innovative drugs to move from the laboratory to clinical application. The simultaneous launch of the GCK-01 combination therapy at the two sites will enable the rapid exploration of the therapy’s safety boundaries and preliminary efficacy signals through scientific trial design and rigorous clinical management, providing key data for the advancement of subsequent clinical phases. The implementation of this study is not only expected to bring a new treatment option for patients with R/R FL, but also will promote the innovative development of cell therapy technology in the field of hematological malignancies, and provide valuable experience for the industry to explore the integrated model of "precision therapy + immunotherapy".  

  We wish the "Phase I Clinical Study on the Safety and Tolerability of GCK-01 Cell Injection Combined with Rituximab in the Treatment of Relapsed or Refractory Follicular Lymphoma" a smooth progression under the collaboration of Ruijin Hospital (Shanghai) and Union Hospital (Wuhan). May it achieve breakthrough results at an early date, bring new hope to lymphoma patients, and make new contributions to the innovative development of the cell therapy field!  

Key Terminology Notes  

  - R/R FL: Relapsed or Refractory Follicular Lymphoma (复发或难治性滤泡性淋巴瘤)  

  - MTD: Maximum Tolerated Dose (最大耐受剂量)  

  - RP2D: Recommended Phase II Dose (II期临床推荐剂量)  

  - Open-label: A clinical trial design where both researchers and participants know the treatment being administered (开放标签，原文“盲法：开放”对应表述)  

- Single-arm trial: A clinical trial design without a control group, where all participants receive the same experimental treatment (单臂试验，原文“设计类型：单臂试验”对应表述)